Daewon Lee

Prof. Dr. Daewon Lee

Department of Photonics and Nanoelectronics, Hanyang University, Seoul, Republic of Korea
+1
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2015 in International Journal of Control, Automation, and Systems
Verified
Journal Article
Closed access
PDF file
FGFarhad/Goodarzi Goodarzi
Farhad/Goodarzi Goodarzi
Daewon LeeDaewon Lee
Daewon Lee
TLTaeyoung Lee
Taeyoung Lee

12 July 2023 in Nature
Verified
Journal Article
Closed access
PDF file
Daewon LeeDaewon Lee
Daewon Lee
SCSeongkyu Cho
Seongkyu Cho
CPCheolheon Park
Cheolheon Park
KPKyung Ryoul Park
Kyung Ryoul Park
JLJongcheon Lee
Jongcheon Lee
SKSunghoon Kwon
Sunghoon Kwon

20 November 2018 in Advanced Science
Verified
Journal Article
Open access
PDF file
SSSeo Woo Song
Seo Woo Song
SKSu Deok Kim
Su Deok Kim
DODong Yoon Oh
Dong Yoon Oh
YLYongju Lee
Yongju Lee
ALAmos Chungwon Lee
Amos Chungwon Lee
SKSunghoon Kwon
Sunghoon Kwon
Large‐scale screening of sequential drug combinations, wherein the dynamic rewiring of intracellular pathways leads to promising therapeutic effects and improvements in quality of life, is essential for personalized medicine to ensure realistic cost and time requirements and less sample consumption. However, the large‐scale screening requires expensive and complicated liquid handling systems for automation and therefore lowers the accessibility to clinicians or biologists, limiting the full potential of sequential drug combinations in clinical applications and academic investigations. Here, a miniaturized platform for high‐throughput combinatorial drug screening that is “pipetting‐free” and scalable for the screening of sequential drug combinations is presented. The platform uses parallel and bottom‐up formation of a heterogeneous drug‐releasing hydrogel microarray by self‐assembly of drug‐laden hydrogel microparticles. This approach eliminates the need for liquid handling systems and time‐consuming operation in high‐throughput large‐scale screening. In addition, the serial replacement of the drug‐releasing microarray‐on‐a‐chip facilitates different drug exchange in each and every microwell in a simple and highly parallel manner, supporting scalable implementation of multistep combinatorial screening. The proposed strategy can be applied to various forms of combinatorial drug screening with limited amounts of samples and resources, which will broaden the use of the large‐scale screening for precision medicine.

26 June 2019 in Small
Verified
Journal Article
Closed access
PDF file
OKOkju Kim
Okju Kim
Daewon LeeDaewon Lee
Daewon Lee
ALAmos Lee
Amos Lee
YLYongju Lee
Yongju Lee
HBHyung Jong Bae
Hyung Jong Bae
SKSunghoon Kwon
Sunghoon Kwon

19 December 2016 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
YSYounghoon Song
Younghoon Song
YJYunjin Jeong
Yunjin Jeong
TKTaehong Kwon
Taehong Kwon
Daewon LeeDaewon Lee
Daewon Lee
DODong Yoon Oh
Dong Yoon Oh
SKSunghoon Kwon
Sunghoon Kwon
Although droplet microfludics is a promising technology for handling a number of liquids of a single type of analyte, it has limitations in handling thousands of different types of analytes for multiplex assay.

4 February 2020 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
ALAmos Lee
Amos Lee
JSJessica Svedlund
Jessica Svedlund
EDEvangelia Darai
Evangelia Darai
YLYongju Lee
Yongju Lee
Daewon LeeDaewon Lee
Daewon Lee
SKSunghoon Kwon
Sunghoon Kwon
Liquid biopsy holds promise towards practical implementation of personalized theranostics of cancer. In particular, circulating tumour cells (CTCs) can provide clinically actionable information that can be directly linked to prognosis or therapy decisions. In this study, gene expression patterns and genetic mutations in single CTCs are simultaneously analysed by strategically combining microfluidic technology and in situ molecular profiling technique. Towards this, the development and demonstration of the OPENchip (On-chip Post-processing ENabling chip) platform for single CTC analysis by epithelial CTC enrichment and subsequent in situ molecular profiling is reported. For in situ molecular profiling, padlock probes that identify specific desired targets to examine biomarkers of clinical relevance in cancer diagnostics were designed and used to create libraries of rolling circle amplification products. We characterize the OPENchip in terms of its capture efficiency and capture purity, and validate the probe design using different cell lines. By integrating the obtained results, molecular analyses of CTCs from metastatic breast cancer (HER2 (ERBB2) gene expression and PIK3CA mutations) and metastatic pancreatic cancer (KRAS gene mutations) patients were demonstrated without any off-chip processes. The results substantiate the potential implementation of early molecular detection of cancer through sequencing-free liquid biopsy.